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Abstract 
Parkinson´s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease, affecting around 2% of the population with more than 65 years.  
The first gene implicated with PD was SNCA that encodes to alpha-synuclein. At the 
neuronal level, this protein was found in the Lewy Bodies, one of the pathologic 
hallmarks of the disease and it has been identified both in sporadic and familiar cases 
of PD. Its role in the disease is still unclear. Besides alpha-synuclein, other 15 genetic 
loci have been associated to PD.  
To clarify the role of alpha-synuclein in PD, several in vivo models have been 
developed, expressing wild-type and PD-associated mutant forms of the protein. 
However, none of the existing models fully recapitulates all of the hallmarks of the 
disease. To circumvent this limitation, new models must be developed.  
Zebrafish has been widely used as an animal model for studying several human 
disorders because, besides being a vertebrate, it has all the molecular background and 
bioimaging characteristics suitable for these studies.  
Here, we started to generate a Zebrafish transgenic model for human alpha-synuclein.  
In addition, through bioinformatic analysis, we found that four PD related genes 
encoding ATP13a2, Lrrk2, Synphilin-1, and Glucocerebrosidase, display high homology 
rates when compared to the human gene sequences. Moreover, despite a high 
homology in the entire sequence, specific conserved domains sequences are also 
highly homologous, suggesting a conserved functionality of the genes. 
In situ hybridization of ATP13a2 revealed that, although initially expressed in whole 
embryo’s body, it becomes more restricted to the brain area along the embryonic 
development. 
The generation of this novel PD transgenic model will allow further studies to better 
understand the mechanisms underlying the disease pathology. 
Taken together, these results will provide a novel and powerful system to explore 
more the molecular basis of PD and to open novel avenues for therapeutic 
intervention.  
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Resumo 
A doença de Parkinson (PD) é a segunda doença neurodegenerativa mais comum 
depois da doença de Alzheimer, afectando cerca de 2% da população com mais de 65 
anos. 
SNCA foi o primeiro gene a ser associado a PD, que codifica para a alfa-sinucleína. A 
nível neuronal, esta proteína foi identificada nos corpos de Lewy, uma das principais 
características da doença, tanto em casos esporádicos como em casos familiares de 
Parkinson. O seu papel na doença ainda não foi desvendado. Além da alfa-sinucleína 
outros genes têm sido associados a casos familiares da PD. 
Para esclarecer a sua função, têm sido desenvolvidos vários modelos in vivo, 
expressando as formas nativas e mutadas da proteína. No entanto nenhum foi capaz 
de recapitular todas as características da doença, especialmente em termos 
fenotípicos e comportamentais. Este facto levou à necessidade de gerar novos 
modelos.  
 Zebrafish tem sido amplamente utilizado como modelo animal e, para além de ser um 
vertebrado, apresenta as ferramentas moleculares e de bioimagiologia  necessárias 
para ser utilizado como um modelo de doenças neurodegenerativas.   
Neste trabalho, iniciámos a criação de um modelo de zebrafish transgénico, 
expressando alfa-sinucleína humana. Além disso, através de análise bioinformática, 
concluimos que quatro genes relacionados com PD: ATP13a2, LRRK2, sinfilina-1 e 
glucocerebrosidase apresentam uma elevada taxa de homologia em comparação com 
os respectivos genes humanos. Esta homologia estende-se aos domínios funcionais 
que são idênticos entre as sequências indicando uma funcionalidade conservada dos 
genes. 
Através da técnica que hibridização in situ, demonstrámos que o gene ATP13a2 tem 
uma expressão ubíqua ao longo do corpo de Zebrafish durante as fases iniciais do seu 
desenvolvimento  embrionário, sendo essa expressão mais localizada no cérebro em 
estadios mais avançados.   
Em conjunto, estes resultados vão abrir uma nova perspectiva sobre a etiologia da PD. 
Palavras-chave: Doença de Parkinson, Zebrafish, a-syn, ATP13a2, modelo genético, Bio-
informática 
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List of abbreviations 
 
a-syn Alpha-synuclein 
Blast Basic local alignment search tool 
bp Base pairs 
dpf Days post fertilization 
GBA Glucocerebrosidase 
GFP Green fluorescent protein 
hpf Hours post fertilization 
IRES Internal ribosome entry site 
kDa kilo Dalton 
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Lrrk2 Leucine-rich repeat kinase 2 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
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1. Introduction 
 
1.1 Parkinson´s Disease 
Parkinson’s disease (PD) was first described in 1817 by James Parkinson and is the 
second most common neurodegenerative disorder, after Alzheimer´s disease. PD is 
characterized by motor and non-motor features. The most common motor symptoms 
are tremor, rigidity, akinesia (reduction in movement) and bradykinesia (slowed 
movement) that occur mainly due to the degeneration of dopaminergic neurons, 
involved in the movement coordination and located in the substantia nigra pars 
compacta (Figure 1). However, in later stages of the disease it affects other brain 
regions [1, 2]. The degeneration of these wider circuits in the brain is responsible for 
the non-motor features of the disease, such as cognitive decline, depression and, in 
some cases, hallucination episodes. 
 
 
 
Figure 1. Spatial location of the substantia nigra in human brain. In PD patients it is visually possible to 
detect a depletion of dopaminergic neurons in the substantia nigra which is responsible for the majority 
of the motor symptoms found in the disease. Adapted from http://adam.about.com/reports/Parkinson-
s-disease.htm and http://nihseniorhealth.gov/parkinsonsdisease/whatcausesparkinsonsdisease/02.html 
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The majority of the PD cases are sporadic and only 2% of the cases are familiar, being 
associated to specific gene mutations. Phenotypically, both PD forms are very similar 
regarding motor symptoms, suggesting that the insult responsible for the disease 
development and progression may be identical in both cases [3, 4]. 
The major pathologic hallmark of PD, besides the degeneration of dopaminergic 
neurons, is the presence of cytoplasmic protein inclusions named Lewy Bodies (LBs) 
that can be found in the remaining surviving neurons. These inclusions are mainly 
constituted by alpha-synuclein (a-syn) which was the first protein to be associated to 
the disease. The role of these bodies is still unknown, however it is believed that they 
may present a protective effect in the disease, by sequestering dysfunctional and toxic 
protein species responsible for neurodegeneration [5]. In agreement, there is an 
increasing hypothesis suggesting a toxic role at a cellular level in PD via oligomeric 
species formation of a-syn [6, 7]. Those intermediate species might be more toxic than 
the larger protein inclusions, whose formation represents a survival strategy to protect 
neurons from the toxicity induced by a-syn intermediate oligomers.  
There are three known a-syn mutations linked to PD that are the result of missense 
alterations: A30P, E46K and A53T. The association of a-syn with PD was first identified 
due to the A53T mutation, which promotes autosomal dominant familial PD [8]. At a 
biochemical glance, this mutation is characterized by a disruption of the ubiquitin 
proteasome system and by a marked accumulation of autophagic-vesicular structure 
[9] . 
The A30P mutation abolishes the ability of a-syn to bind to lipid vesicles [10] and in 
yeast this mutated protein is found in cytoplasm and not in the plasma membrane as 
the wt and A53T proteins [11]. More recently, it was found that this mutation stabilizes 
a-syn against proteasomal degradation triggered by heme oxygenase-1 overexpression 
[12].  
Little is known about the third discovered mutation, E46K, at the exception that it 
promotes amyloid fibril formation [13] and leads to an atrophy of the substantia nigra 
and LBs formation [14]. 
Interestingly,  triplication of the region that contains the a-syn gene and flanking 
regions was identified in PD and dementia with LBs [15]. 
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Besides PD, a-syn is the common divisor in several neurodegenerative diseases called 
synucleinopathies, like Multiple System Atrophy and Dementia with LBs. 
 
 
1.2 PD-associated genes 
 
Since 1998, with the discovery of a-syn, several genes have been associated to PD: 
PARKIN, ubiquitin carboxyl-terminal esterase L1 (UCHL1), phosphatase and tensin 
homolog (PTEN)-induced putative kinase 1 (PINK1), DJ-1, Leucine-rich repeat kinase 2 
(Lrrk2), ATP13a2, synphilin-1, glucocerebrosidase among others (Table 1).  
Table 1. Known genetic loci linked to Parkinson’s disease 
mutation gene locus Lewy Bodies onset/age inheritance 
Park 1 a-syn 4q21 yes 40s AD 
Park 2 Parkin 6q25 no 20s AR 
Park 3 ? 2p13 yes 60s AD 
Park 4 a-syn 4q21 yes 30s AD 
Park 5 UCH-L1 4p15 yes 50s AD 
Park 6 PINK1 1p35 ? 30s AR 
Park 7 DJ1 1p36 ? 30s AR 
Park 8 Lrrk2 12p ? 40s AD 
Park 9 ATP13A2 1p36 ? 10s AR 
Park 10 ? 1p32 ? 50s ? 
Park 11 GIGYF2 2q36-37 ? late AD 
Park 12 ? Xq21-q25 ? ? X-chromosome 
Park 13 HTRA2 2p12 ? 50s ? 
Park 14 PLA2G6 18q11 ? ? AR 
Park 15 FBXO7 22q12-q13 ? ? AR 
Park 16 ? 1q32 ? ? ? 
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1.2.1 Alpha-synuclein 
 
a-syn belongs to a family of three distinct genes, a-, β- and γ-synuclein which have only 
been found in vertebrates [16]. These proteins show a highly conserved alpha-helical-
rich amino-terminal domain that is mainly unfolded in solution but can shift to an α-
helical conformation upon interaction with lipid structures. 
The carboxy-terminal domain is rich in proline and acidic residues like glutamate and 
aspartate. The central hydrophobic domain of a-syn contains a specific domain known 
as NAC (non-Aβ component of AD amyloid). This region has been implicated in 
Alzheimer’s disease as the second main component of amyloid plaques. It is 
responsible for specific protein-protein interactions and is believed to contribute to an 
a-syn conformation change towards an aggregation-prone β-sheet structure [17] 
(Figure 2). 
 
 
 
 
 
 
 
Figure 2. a-syn protein domains. The NAC domain is responsible for the protein structure instability, 
intrinsically prone to be unfolded. The three mutations are found in the N-terminal domain. 
 
a-syn is a small 140 amino-acid protein with a molecular weight of 14.5 kDa, 
abundantly expressed in the brain, which is enriched in neural pre-synaptic terminals. 
Its role in normal or pathological conditions is still unclear. Although its function 
remains poorly unknown, a-syn has been associated to vesicular trafficking since its 
cytoplasm accumulation inhibits the vesicular traffic between the endoplasmic 
reticulum and the Golgi complex [18]. This protein has been also associated with the 
neuronal signaling in several steps: vesicle reserves, where the absence of the protein 
leads to a decrease in the reserve pool of synaptic vesicles [19, 20]; 
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Vesicle release: in some cell lines, the a-syn  overexpression impairs the release of 
neurotransmitters [21].  Moreover, it has been shown that a-syn plays a role in the lipid 
transport and in the biogenesis of the synaptic membrane. It is thought that its 
structural characteristics (amphipathic α-helical domains) are reminiscent to those of 
the class A2 apolipoproteins, responsible for lipid molecules trafficking [22]. Also in 
vesicle recycling since a-syn is implicated in the endocytic recycling of synaptic vesicles, 
following neuronal stimulation by interaction with polyunsaturated fatty acids[23].  
In the disease, a-syn has also been implicated in cell death due to the toxicity exhibited 
by its  oligomeric species [6, 24, 25]. 
 
1.2.2 Lrrk2 
 
Lrrk2 is a 2527 amino-acid protein which was first associated with PD in 2004 and is 
now considered as the most important autosomal-dominant origin of PD [26]. Lrrk2 is 
a large protein (286kDa) with several predicted conserved domains (Figure 3): a 
Leucine-rich repeat (LRR), a WD40 domain, a mitogen-activated protein kinase kinase 
kinase domain (MAPKKK), a Ras in complex proteins (ROC), a C-terminal of Roc (COR) 
domain, and an Ankaryne repeat.  
The LRR, WD40 and Ankaryne regions can be found in several other proteins and they 
are involved with different molecules interactions such as cytoskeleton proteins, 
transcription factors, and signaling and cell cycle regulators. COR and ROC are found 
together in ROCO family of GTPases. The function of the former domain is still 
unknown but the latter might regulate vesicle formation, actin- and tubulin- 
dependent vesicle movement, and membrane fusion, a role similar to the Ras-
associated binding-GTPase (Rab) family of proteins [27]. The MAPKKK domain of Lrrk2 
belongs to the super-family of serine/threonine and tyrosine kinases, which have an 
important role in cell survival and cell death pathways in response to intracellular or 
extracellular stress [28]. 
There are several mutations identified in Lrrk2, but only few were linked to a PD 
pathogenic effect: GS2019S, I2020T, both in the MAPK domain [29, 30], R1441C and 
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R1441G in the ROC domain, and Y1699C, that is found in the COR domain. The first one 
is responsible for 0,5-2,0% of the sporadic cases of PD . 
 
 
Figure 3. Human Lrrk2 functional domains. Lrrk2 is the biggest protein linked to PD and is responsible 
for the majority of the familial cases of the disease. It has several functional domains: Ankyrin (ANK), 
Leucine-rich repeat (LRR), Ras in complex proteins (ROC), a C-terminal of Roc (COR), mitogen-activated 
protein kinase kinase kinase domain (MAPKKK), and a WD40 domain. 
 
This protein can be found in brain, lungs, kidney, spleen and leucocytes [31-35]. In the 
rat brain it can be found at high concentrations (both mRNA and protein levels) in the 
dorsal striatum and cortex and also at lower levels in the substantia nigra[36]. 
Inside the cell, Lrrk2 is present in the cytoplasm [37] and associated with the 
mitochondria [38, 39]. Moreover, it can also be found in lipid rafts on the cellular 
membrane of organelles like golgi, endoplasmic reticulum and synaptic vesicles. In 
fact, Lrrk2 was suggested to play a role in the regulation of the vesicle synthesis, 
transport and secretion and also in the regulation of membranous structures [40]. 
Lrrk2 has both a GTPase and a kinase domain, exhibiting a dual enzymatic activity. 
Lrrk2 GTPase activity seems to regulate its kinase activity. Mutations in the first 
domain promotes its kinase activity [39, 41] while the opposite does not have an effect 
on the GTPase activity[42]. 
 
1.2.3 ATP13a2 
 
In 2006, ATP13A2 was initially identified as the gene responsible for Kufor-Rakeb 
syndrome in two families. The disease is characterised by sub acute, juvenile-onset, 
levodopa-responsive parkinsonism, pyramidal signs, dementia and a supranuclear gaze 
palsy which consists in the inability to look in a particular direction.  
ATP13A2 belongs the P5 subfamily of P-type transport ATPases, a transporter  family 
with unknown substrate specificity [43]. A more recent phylogenetic study 
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shows the relationship between the different orthologs of these proteins and the 
presence of duplications of ATP13A2 in mice and humans, but not in lower vertebrates 
[44].  
Two loss-of-function mutations in this protein were found in a early on-set hereditary 
parkinsonism case [45]. 
 
 
1.2.4 Synphilin-1 
 
Synphilin-1, also known has a-syn interacting protein (SNCAIP), is also present  in LBs 
[46]. The interaction with a-syn has been seen in vivo [47] an the co-expression of the 
two proteins in cell culture, were enough to form LB-like inclusions [48].  
Besides a-syn, synphilin-1 also interacts with parkin[49] and Lrrk2 [50] suggesting that 
it has an important role both in sporadic and familial cases of PD.  
The gene has also been found mutated (R621C) in two different PD cases [51]. 
 
 
1.2.5 Glucocerebrosidase 
 
Mutations in Glucocerebosidase (GBA) are found in Gaucher’s disease. These 
mutations reduce or eliminate the activity of beta-glucocerebrosidase in cells. As a 
result, glucocerebroside is not properly processed. This protein can accumulate in 
macrophages and damage the spleen, liver, bone marrow, and other organs. More 
recently, this protein has been linked to Parkinson [52]. Some of the characteristics 
found in Guacher’s disease are identical to PD patients: tremor, bradykinesia, rigidity 
and often cognitive decline [52, 53]. In 2004, has been proven that PD patients have 
higher rates than expected of GBA in mutated form [54]. 
 
 
1.3 Zebrafish as a model organism in PD  
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To better understand the chemical, physiological and pathological effects of a-syn, in 
vivo experiments with animal models overexpressing the normal and mutant variants 
of this protein have been generated. Previous experiments using invertebrate models 
like Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila melanogaster 
proven to be useful in the study of PD [55].  
Saccharomyces cerevisiae started to be used as a simple and versatile tool in high-
throughput analysis, allowing researchers to understand the main mechanisms 
underlying a-syn-mediated cellular degeneration. The first genetic screen in yeast 
identified 86 yeast deletion mutants with enhanced a-syn toxicity. Several of these 
mutants lacked functions involved in lipid metabolism, vesicular transport, ubiquitin 
proteasome system, and defenses against oxidative stress or mitochondrial activities. 
[56]. 
Transgenic models in Caenorhabditis elegans and Drosophila melanogaster showed 
that a-syn overexpression led to the loss of dopaminergic neurons, resulting in motor 
coordination defects. In D. melanogaster this is an age-dependent effect [55, 57]. 
Nevertheless, there is a great disadvantage in invertebrate models of PD which is the 
different nervous system complexity compared to higher species. Moreover, these 
models lack endogenous a-syn [58]. 
On the other hand, several lines of transgenic mice have also been generated based on 
toxins and genetic approaches. Several toxins like 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), paraquat, epoxomicin, rotenone, 6-hidroxy dopamine have 
been proven to promote a parkinson-like behavior. MPTP, paraquat and rotenone are 
mitochondrial complex I inhibitors although they act through different mechanisms. 
The first two are specific for dopaminergic neurons while rotenone has a systemic 
effect. Epoxomicin is a proteossomal inhibitor being able to recapitulate most of the 
PD key hallmarks. In terms of genetic approaches, both overexpression
or knock-out of specific PD related genes like a-syn, DJ-1, Parkin and Lrrk2 have been 
performed (reviewed at [59]). 
The phenotypic results, however, do not resemble all the PD features. In some cases, it 
was evidenced a neuronal accumulation of a-syn [60] while in other models only few 
symptoms were attributed to the neurodegeneration of motor neurons [61].  
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To overcome this issue, Danio rerio, commonly designated as zebrafish, is now being 
used as an intermediate model between D. melanogaster and mice. This model has the 
advantage of being a vertebrate and therefore is phylogenetically closer to humans 
than drosophila, easier to maintain than mice, with a short life cycle and, importantly, 
presents a nervous system similar to humans[62].  
In general, animal models must present certain features: a small life cycle, low 
maintenance cost, large number of descendants, and an easy manipulation. Zebrafish 
share all these aspects together with the advantage of being less expensive than mice. 
Moreover, due to its optical transparency during the different embryo stages, with the 
use of fluorescent reporters it allows in vivo gene expression and different cellular 
processes monitoring [63]. 
To develop a neurodegenerative model, the following properties in the regulatory 
elements must be verified: the gene/protein expression must occur in a controllable 
range of neurons, to investigate their role in different neurons sub-populations; the 
gene/protein expression cannot lead to an early death phenotype, since the main goal 
is to study their late effects in neurodegeneration; the animal must live until 
adulthood; the gene/protein expression must persist until adult age and finally the 
gene/protein expression must lead to a visible phenotype [64]. 
Zebrafish is thus an ideal organism to study neurodegeneration. Being a vertebrate, 
the basic organization and division of the nervous system is similar to other 
vertebrates, including humans [62]. The zebrafish central nervous system (CNS) 
contains specialized neuronal populations of direct relevance to human 
neurodegenerative diseases, for example dopaminergic neurons [65], cerebellar 
Purkinje cells [66] and motor neurons [67]. In addition, CNS also contains the human 
homologues of oligodendrocytes and astrocytes, which may play central roles in 
neurodegeneration through critical neuro-glial interactions. Therefore, Zebrafish can 
be used as a model system for neurodegenerative diseases. 
Interestingly, zebrafish expresses several highly conserved and engodenous genes 
associated with human PD, including DJ-1 [68], Parkin [69], Pink1 [70], UCH-L1 [71] and 
three human synuclein orthologues also known as sncga, sncgb, and sncb [72]. 
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The dopaminergic system in zebrafish homolog to the human one is located in the 
ventral diencephalon [73]. Treatment with MPTP showed a direct effect on these 
diencephalic dopaminergic neurons. This results in a loss of diencephalic dopaminergic 
neurons and an aberrant swimming pattern, indicating that MPTP may lead to 
zebrafish motor impairment, a known PD feature [74]. Therefore, Zebrafish should be 
a good model to study this disease and the generation of transgenic lines is the next 
step to achieve this goal.  
Besides all the advantages of Zebrafish, it also has some disadvantages when 
compared to other models. They aren’t mammals, so they are not as closely related to 
human as mice, therefore, all the new discoveries must later be verified in a mammal 
model. When compared to D. melanogaster, the number of genetic-based tools are 
much less, making fly a better model for those type of studies. 
Here, we propose to develop transgenic lines overexpressing a-syn, by genome 
insertion in the zebrafish so it can be transmitted to the next generations.  
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2. Objectives 
 
The main goal of this project was to create the first a-syn transgenic zebrafish line 
using human wild-type a-syn and GFP. We chose the Tyrosine Hydroxylase (TH) 
promoter to drive expression of the gene specifically in dopaminergic neurons. 
 A secondary objective was to investigate the presence of homologues genes of PD in 
zebrafish through bioinformatic analysis.  
We believe that this model will recapitulate central aspects of PD, constituting a 
powerful in vivo model to study the molecular basis of the disease. 
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3. Methods 
 
To generate the transgenic zebrafish lines: 
3.1  Development of the constructs  
 
The following constructs were generated: THrat:IRES:GFP, THrat:a-syn:IRES:GFP and 
THzeb:GFP (Figure 4) in  pminitol2 vector (Annex1). The IRES:GFP sequence was obtain 
from the  pIRES-hrGFP-1, a vector from stratagene (Annex 2).  
 
 
 
 
Figure 4.  Constructs created for the generation of transgenic zebrafish. The constructs are on pMinitol 
vector. A) THrat:a-syn:IRES:GFP with the total size of 9170bp. B) THrat:IRES:GFP with 8747bp. C) The 
control construct Thzeb:GFP is the smaller with 8163bp. 
 
The constructs were linearized and then co-injected with the mRNA transposase. There 
are two main techniques to achieve the insertion of a construction for the generation 
of transgenic lines: the use of the Tol2 transposase technique or the pseudotype 
retroviral technique. 
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The Tol2 transposase system is based on the use of a specific vector (pminitol2) which 
has two tol2 sequences at its extremities and a tol2 transposase mRNA. Tol2 element 
has 4.7 kb in length and contains a gene encoding a transposase protein [75]. The 
transcribed mRNA encodes for the transposase protein fully functional that catalyzes 
the transposition of a non-autonomous Tol2 construct [75, 76]. This transposition in 
the genome can be used up to 11 kb sequences with a single-copy insertion [77].  The 
rate of success ranges from 20% to 70% concerning the germline transmitting founder 
fish [77, 78]. The co-injection of the vector with the construct and the transposase 
mRNA will result in the translation of mRNA transposase which might catalyze the 
construct excision from the pminitol2 vector leading to a stable integration of the 
excised DNA in the genome (Figure 5). 
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Figure 5.  Tol2 tranposase technique. Schematic showing a co-injection, in one cell stage, of the mRNA 
transposase with the linearized construct in a specific vector. This will result in single-copy mode 
insertion in the genome. The fish that will achieve adulthood will be outcrossed and create the F1 
generation. Adapted from [79]. 
 
The second technique consists on the injection of a pseudotype retrovirus in the 
blastula-stage embryos generating a chromosomal integration of its cDNA. The proviral 
insertion is transmitted to F1 generation and, although it becomes a germline 
transmitting founder fish with a 100% of efficacy, handling and modifying these 
retroviral vectors is more  difficult  when compared to Tol2 manipulation and construct 
generation [80, 81]. Because of this disavantage, the Tol2 tranposase technique was 
chosen. 
 
3.2 Microinjection 
 
Injections were performed using a Leica M165C stereomicroscope and a Pneumatic 
Picopump PV820 microinjection device (World Precision Instruments).  
Injection volume was setup in mineral oil using the highest magnification objectives 
(40x) to achieve the highest precision. 
An injection volume of 4 nL was used since smaller volume injection prevents 
malformations in contrast to a higher volume one. Eggs were injected in the yolk sac at 
the one cell stage. They were also injected with rhodamine to ensure that the injection 
process was correctly performed. Embryos were raised at 28°C. During the first hours 
after injections and in the following 5 days, the medium was replaced and the embryos 
were evaluated using a stereomicroscope: dead and/or unfertilised eggs were 
removed and surviving embryos were counted. Embryos expressing high fluorescence 
levels were kept growing before they were crossed with Wt zebrafish to investigate for 
potential founders (the founder fish crossed with Wt fish will generate a progeny with 
10-15% green fluorescent embryos). 
 
Zebrafish: a new model of Parkinson’s disease|                                                                      Methods 
 
   15 
3.3 Zebrafish culture and maintenance  
 
Zebrafish were maintained at 28°C on a 14 hour light / 10 hour dark cycle. They were 
housed in multi-tank flow through systems under standardised environmental 
conditions including continuous aeration, filtration, ultraviolet sterilization, and daily 
water replacement (10% of total circulating volume). Breedings were set up using a 1:1 
male to female ratio. Embryos were collected during the morning and maintained in 
10cm Petri dishes with a maximum of 80 embryos per dish. They were raised at 28°C in 
Petri dishes with embryo medium until they achieve 5 days of growth. At 5 days post-
fertilization (dpf), the larvae were placed in 1 liter tanks filled with system water and 
fed with paramecia.  
 
 
 
3.4 Blasting 
 
The amino-acid sequences of human ATP13a2, Lrrk2, synphilin-1 and 
Glucocerebrosidade were blasted against the zebrafish genome sequence using 
Ensembl’s website at www.ensembl.org [82].  
 
3.5 Phylogenetic tree and Functional analysis 
 
The blast highest scored sequences for each gene were chosen. To determine the 
phylogenetic proximity between each human and zebrafish sequences, protein 
sequences multiple alignment was performed  with Clustal-X2 [83]. BioEdit software 
was used to visualize the phylogenetic tree and to determine the “identity” and 
“similarity” between the homologues sequences. Blosum62 matrix was used to obtain 
the similarity values [84]. 
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Functional Analysis was determine with the software S.M.A.R.T provided by 
http://smart.embl-heidelberg.de/ [85] and the Reverse psi-blast program available at 
http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi [86].  
 
To characterize both spatially and temporally the expression of ATP13a2 
and Lrrk2: 
 
3.6 Design of probes for in-situ hybridization 
 
Forward and reverse primers for ATP13a2 (CCTGACACTGAACCCCTCAT and 
CACTATCAAACAGGCCATGC, respectively) and LRRK2 (CCCTAAACCGCAGAGTATCA and 
ATTCATAGTCCACCGGTCTG) were chosen using the online version of the software 
Primer3 [87].  Total mRNA from 70 embryos with 24 hours was obtained using RNeasy 
mini Kit from Qiagen. The mRNA was transcribed to cDNA with Reverse Transciptase 
Polimerase Chain Reaction (RT-PCR) technique using Phusion enzyme from Finnyime.  
PCR was performed to get the specific 762bp ATP13a2 cDNA sequence. The fragment 
was transcribed in two different RNA probes with digoxigenine labeled nucleotides, 
using specific RNA polymerases (SP6 and T7 from Promega). These probes (anti-sense 
and sense) were further used in in situ experiments. The sense probe works has a 
control probe. Its sequence is identical to the sequence of the gene mRNA and 
therefore no interaction between the two is possible. The anti-sense probe has a 
complementary sequence to the mRNA of our gene so they will interact and form 
stable dsRNA. 
 No results for LRRK2 WISH will be presented since the sense probe (control) 
showed signaling indicating that it was hybridizing with some mRNA in the embryo. 
Therefore no conclusions could be taken and new primers were designed. 
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3.7 Whole mount In-situ hybridization 
 
The in situ hybridization technique allows the expression pattern of a particular gene 
to be detected. In Zebrafish, this expression analysis can be done in the entire embryo 
due to its transparency in the early stages. Embryos with more than 24hpf were 
treated with 1-Phenyl-2-thiourea (PTU), a reagent that eliminates the natural 
pigmentation that starts to appear around the 23hpf. 
The RNA probes with digoxigenine labeled nucleotides will dimerize with the mRNA 
that is present in the embryo forming stable dsRNA. An antibody for digoxigenine will 
recognizes these dsRNA and an enzymatic reaction will originate a purple color. Throw 
this purple color we are able to analyze the pattern of expression in the embryo. 
Two sets of in-situ with the sense and anti-sense probes were done for ATP13a2 using 
embryos with 12, 24, 48, 72 hours and 6 days of life. This provides a temporal and 
spatial knowledge of the gene expression pattern during zebrafish embryonic 
development. The protocol was done accordingly to [88] . 
 
3.8 Epifluorescence Microscopy 
 
All images from tg Zebrafish and from in situ experiments were acquired using the 
Leica MZ10F microscope. 
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4. Results 
 
Transgenic zebrafish lines for PD using human a-syn were initiated.  To validate this model it 
will be required subsequent validation.  
We also investigated four zebrafish orthologues of PD- associated genes using a bioinformatic 
approach, and found that the homology between the two species is high. In particular, the 
expression analysis of ATP13a2 revealed that the gene is expressed during embryonic 
development at different locations throughout the development which can reflect a 
differential role in neurogenesis. 
Overall, these data point Zebrafish as an interesting model to study PD and other 
neurodegenerative disorders. 
 
4.1 Generating the transgenic zebrafish lines 
 
Three different DNA constructs were developed to generate three independent 
transgenic lines: THrat:a-syn:IRES:GFP, THrat:IRES:GFP and THzeb:GFP. The construct 
THrat:a-syn:IRES:GFP will generate the first stable transgenic line expressing the 
human a-syn. The other two constructs will generate two control lines expressing the 
EGFP under the control of rat TH (THrat) or zebrafish TH (THzeb), respectively. The 
work is part of a wider project that aims the development of several zebrafish 
transgenic lines of PD. 
Those constructs were already microinjected in one cell stage embryos and they were 
checked for EGFP expression. Different concentrations of the constructs and mRNA 
transposase were initially tested with THrat:IRES:GFP. The lowest concentration 
resulting in protein fluorescence detection was 30ng/µl DNA: 25ng/µl mRNA 
transposase. However, as the intensity level of fluorescence at 48 hpf was very low 
(Figure 6 A-B), higher concentrations were investigated. The top concentration used to 
generate the founder fish was 80 ng/µl DNA: 50 ng/µl mRNA transposase. Higher DNA 
concentrations lead to an increased anatomical problems and higher lethality. With 
Zebrafish: a new model of Parkinson’s disease                                                                        | Results 
 
 
19 
the latter concentration, at 10 dpf, it is possible to detect protein fluorescence 
especially in the eye area (Figure 6 C-D). The expression pattern in adult brain will be 
analyzed in the F1 generation. For the THrat:a-syn:IRES:GFP, the same concentrations 
were investigated. It is possible to detect protein fluorescence at 48 hpf and 10 dpf. At 
10 dpf the fluorescence is also localized in the retina (Figure 6 E-F). 
In the THzeb:GFP construct, the DNA concentration ratio of 30 ng/µl:25 ng/µl mRNA 
transposase was enough to detect strong green fluorescence in all body of 
microinjected fish, designated as potential founders (Figure 6 G-H). All potential 
founders will grow until adulthood and then each one will be crossed with Wt 
zebrafish and positive, fluorescent, F1 generation is expected.   
The protein expression pattern is more relevant in the fish brain and in the eye (Figure 
G-H). 
No fluorescence is seen in control, non-injected, fish (Figure 6 I-J).  
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Figure 6. PD transgenic Zebrafish protein fluorescence. A-B) Low levels of fluorescence detectable with 
30ng/µl DNA: 25ng/µl for the THrat:IRES:GFP construct injection at 48hpf. C-D) Founder Fishes protein 
fluorescence for THrat:IRES:GFP construct injection with 80ng/µl DNA: 50ng/µl mRNA transposase at 
10dpf. E-F) Fishes injected with the construct THrat:a-syn:IRES:GFP at 48hpf and 10dpf. G-H) THzeb:GFP 
founder fishes with high protein fluorescence levels at 96hpf. I-J) Absence of protein fluorescence 
detection in non-injected zebrafish. Scale bar: 200µm 
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For the THzeb:EGFP construct, the potential founders fishes already reached 
adulthood and were crossed with wt fishes  with a positive F1 generation being 
obtained. In this F1 the expression is localized in the brain (Figure 7 A-B) 
 
Figure 7. F1 positive Generation. The outcross of the founder fishes with the construct THzeb:EGFP 
revealed embryos with fluorescence. This fluorescence is focused in the brain area. Scale bar 200µm 
 
 
4.2 Bioinformatic analysis revealed high degree of conservation of PD-
associated genes between Human and Zebrafish 
 
Since a-syn, 15 more genes were associated to PD [68-71]. From those, we focused our 
attention in the four genes linked to PD less explored: ATP13a2, Lrrk2, Synphilin-1 and 
Glucocerebrosidase. A search for a-syn has also performed but no sequence was found 
in zebrafish genome so far. 
The blast the protein sequences of the four studied genes against Zebrafish genome 
revealed one high score match for each. 
 
 
4.2.1 Zebrafish has one orthologue for Human ATP13a2-5 
 
The human ATP13A family has five members, ATP13a1-5 (NCBI accession numbers 
NP_065143, NP_071372, NP_078800, NP_115655 and NP_940907 respectively). 
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Blasting the protein sequence of the human ATP13a2 against zebrafish genome 
identified the orthologue zgc:136762. Blasting the protein sequence from zebrafish 
against the human database showed that zgc:136762 was highly homologous to 
ATP13A2, -3, -4 and -5 with 50%, 37%, 38% and 35% of homology, respectively. 
Concordantly, the reverse comparison of those four human protein members 
sequences against the zebrafish genome, identified only zgc:136762 as their 
orthologue.  
For human ATP13a1, the blast showed only one sequence: NP_001001403.1 with a 
homology between them of 74%.  
Zebrafish has two orthologues for the five human ATP13ases protein. zgc:136762 is the 
orthologue of ATP13a2-5. This protein as a higher homology to the human ATP13a2 
and therefore was named ATP13a2. The other zebrafish protein, ATP13a, is identical to 
ATP13a1 (Figure 8-9). These results were confirmed by phylogenetic analysis and they 
confirm that ATP13a2 and ATP13a1 share a higher homology with their zebrafish 
orthologues than with the other human ATP13ases (Figure 9). 
 
ATP13a4_Hu   ---------- --MGHFEKGQ HALLNEGEE- -----NEMEI FGYRTQGCRK  
ATP13a5_Hu   ---------- -MEENSKKDH RALLNQGEE- -----DELEV FGYRDHNVRK  
ATP13a3_Hu   ---------- -----MDREE RKTINQGQE- -----DEMEI YGYNLSRWKL  
ATP13a2_Hu   MSADS---SP LVGSTPTGYG TLTIGTSIDP LSSSVSSVRL SGYCGSPWRV  
zgc_136762   MDAKGNCVPG LDGASSSPDT EPLIKDPRPP ELSLVSHMDV QGYRWVCWKV  
Clustal Co                            :            . : :  **     :   
 
ATP13a4_Hu   SLCLAGSIFS FGILPLVFYW RPAWHVWAHC VPCSLQEADT VLLRTTDEFQ  
ATP13a5_Hu   AFCLVASVLT CGGLLLVFYW RPQWRVWANC IPCPLQEADT VLLRTTDEFQ  
ATP13a3_Hu   AIVSLGVICS GGFLLLLLYW MPEWRVKATC VRAAIKDCEV VLLRTTDEFK  
ATP13a2_Hu   IGYHVVVWMM AGIPLLLFRW KPLWGVRLRL RPCNLAHAET LVIEIRDKED  
zgc_136762   WLCRIGAVFS VGLLLVLFKW RPRIGILARC KSCPISMADV LLLKDRYG--  
Clustal Co               *   ::: *  *   :       . :  .:. :::.        
 
ATP13a4_Hu   IYSWKKVIWI YLSALNSAFG LTPDHPLMT- ---------- -DEEYIINRA  
ATP13a5_Hu   RYMRKKVFCL YLSTLKFPVS KKWEESLVA- ---------- -DRHSVINQA  
ATP13a3_Hu   MWFCAKIRVL SLETYPVSSP KSMSNKLSNG HAVCLIENPT EENRHRISKY  
ATP13a2_Hu   SSWQLFTVQV QTEAIGEGSL EPSPQSQAED GRSQAAVGAV PEGAWKDTAQ  
zgc_136762   ---QQFVVDV ITEEVEEGSL D--------- ----FAVGDA DENEWRDTVQ  
Clustal Co            :   .                               :     .    
 
ATP13a4_Hu   IRKP------ --DLKVRCIK VQKIRYVWNY LEGQFQKIGS LEDWLSSAKI  
ATP13a5_Hu   LIKP------ --ELKLRCME VQKIRYVWND LEKRFQKVGL LEDSNSCSDI  
ATP13a3_Hu   SQTE------ --SQQIRYFT HHSVKYFWND TIHNFDFLKG LDEGVSCTSI  
ATP13a2_Hu   LHKSEEAVSV GQKRVLRYYL FQGQRYIWIE TQQAFYQVSL LDHGRSCDDV  
zgc_136762   LHSE------ -KKTLLRYYV FEGIRYIWIS KKGAFCKASV LSEGWTCADL  
Clustal Co     .          .  :*     .  :*.*       *      *..  :. .:  
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ATP13a4_Hu   HQKFGSGLTR EEQEIRRLIC GPNTIDVEVT PIWKLLIKEV LNPFYIFQLF 
ATP13a5_Hu   HQTFGLGLTS EEQEVRRLVC GPNAIEVEIQ PIWKLLVKQV LNPFYVFQAF  
ATP13a3_Hu   YEKHSAGLTK GMHAYRKLLY GVNEIAVKVP SVFKLLIKEV LNPFYIFQLF  
ATP13a2_Hu   HRSR-HGLSL QDQMVRKAIY GPNVISIPVK SYPQLLVDEA LNPYYGFQAF  
zgc_136762   HGQQ-QGLSR ADQSTRKQIF GANIIDVPVK SYLQLLFEEV LNPFYIFQVF  
Clustal Co   :     **:    :  *: :  * * * : :  .  :**..:. ***:* ** *  
 
ATP13a4_Hu   SVCLWFSEDY KEYAFAIIIM SIISISLTVY DLREQSVKLH HLVESHNSIT  
ATP13a5_Hu   TLTLWLSQGY IEYSVAIIIL TVISIVLSVY DLRQQSVKLH NLVEDHNKVQ  
ATP13a3_Hu   SVILWSTDEY YYYALAIVVM SIVSIVSSLY SIRKQYVMLH DMVATHSTVR  
ATP13a2_Hu   SIALWLADHY YWYALCIFLI SSISICLSLY KTRKQSQTLR DMVKLS--MR  
zgc_136762   SIILWMSDGYf VYYAACIFII SLISIGVSLY ETRKQSTTLR RMACLI--VN  
Clustal Co   :: ** :: *   *: .*.:: : :**  ::* . *:*   *:  :.     :   
 
ATP13a4_Hu   VSVCGRKAGV QELESRVLVP GDLLILTGNK VLMPCDAVLI EGSCVVDEGM  
ATP13a5_Hu   VTIIVKDKGL EELESRLLVP GDILILPG-K FSLPCDAVLI DGSCVVNEGM  
ATP13a3_Hu   VSVCRVNEEI EEIFSTDLVP GDVMVIPLNG TIMPCDAVLI NGTCIVNESM  
ATP13a2_Hu   VCVCRPGGEE EWVDSSELVP GDCLVLPQEG GLMPCDAALV AGECMVNESS  
zgc_136762   VTVRRDTGEE ECVSSEELVP GDCVVIPAEG LLLPCDAALV AGECMVNESM  
Clustal Co   * :        : : *  *** ** :::.      :****.*:  * *:*:*.   
 
ATP13a4_Hu   LTGESIPVTK TPLPKMDSSV P---WKTQSE ADYKRHVLFC GTEVIQAKAA  
ATP13a5_Hu   LTGESIPVTK TPLPQMENTM P---WKCHSL EDYRKHVLFC GTEVIQVKPS  
ATP13a3_Hu   LTGESVPVTK TNLPNPSVDV KGIGDELYNP ETHKRHTLFC GTTVIQTRFY  
ATP13a2_Hu   LTGESIPVLK TALPEG---- ----LGPYCA ETHRRHTLFC GTLILQAR-A  
zgc_136762   LTGESIPVMK TPLSNS---- ----EATYNP ESQRRHTLFC GTQIIQAKGG  
Clustal Co   *****:** * * *.:                    ::*.*** ** ::*.:    
 
ATP13a4_Hu   CSGT-VRAVV LQTGFNTAKG DLVRSILYPK PVNFQLYRDA IRFLLCLVGT  
ATP13a5_Hu   GQGP-VRAVV LQTGYNTAKG DLVRSILYPR PLNFKLYSDA FKFIVFLACL  
ATP13a3_Hu   TGEL-VKAIV VRTGFSTSKG QLVRSILYPK PTDFKLYRDA YLFLLCLVAV  
ATP13a2_Hu   YVGPHVLAVV TRTGFCTAKG GLVSSILHPR PINFKFYKHS MKFVAALSVL  
zgc_136762   GPGKGAIAVV TCTGFLTAKG DLISSILYPQ PLDFRFYRDA MKFLLFLGLL  
Clustal Co        . *:*   **: *:**  *: ***:*: * :*::* .:   *:  *     
 
ATP13a4_Hu   ATIGMIYTLC VYVLSGEPPE EVVRKALDVI TIAVPPALPA ALTTGIIYAQ  
ATP13a5_Hu   GVMGFFYALG VYMYHGVPPK DTVTMALILL TVTVPPVLPA ALTIGNVYAQ  
ATP13a3_Hu   AGIGFIYTII NSILNEVQVG VIIIESLDII TITVPPALPA AMTAGIVYAQ  
ATP13a2_Hu   ALLGTIYSIF ILYRNRVPLN EIVIRALDLV TVVVPPALPA AMTVCTLYAQ  
zgc_136762   ALIGTIYSLV ILSKSNTPWK ELIIRSLDIV TIIVPPALPA AITTATIYAQ  
Clustal Co   . :* :*::               :  :* :: *: ***.*** *:*   :***  
 
ATP13a4_Hu   RRLKKRGIFC ISPQRINVCG QLNLVCFDKT GTLTRDGLDL WGVVSCDRNG  
ATP13a5_Hu   KRLKKKKIFC ISPQRINMCG QINLVCFDKT GTLTEDGLDL WGTVPTADNC  
ATP13a3_Hu   RRLKKIGIFC ISPQRINICG QLNLVCFDKT GTLTEDGLDL WGIQRVENAR  
ATP13a2_Hu   SRLRRQGIFC IHPLRINLGG KLQLVCFDKT GTLTEDGLDV MGVVPLKGQA  
zgc_136762   NRLKRQGVFC ISPPRINICG KISLFCFDKT GTLTEEGLDV WGVMEVTGGV  
Clustal Co    **::  :** * * ***: * ::.*.***** ****.:***:  *          
 
ATP13a4_Hu   FQEVHSFASG QALPWGPLCA AMASCHSLIL LDGTIQGDPL DLKMFEATTW  
ATP13a5_Hu   FQEAHSFASG QAVPWSPLCA AMASCHSLIL LNGTIQGDPL DLKMFEGTAW  
ATP13a3_Hu   FLSPEENVCN EMLVKSQFVA CMATCHSLTK IEGVLSGDPL DLKMFEAIGW  
ATP13a2_Hu   FLPLVP--EP RRLPVGPLLR ALATCHALSR LQDTPVGDPM DLKMVESTGW  
zgc_136762   FGELVP--DP LFLPPGLMLS ALASCHSVAL LGGQALGDPL ELKMIESTGW  
Clustal Co   *            :  . :   .:*:**::   : .   ***: :***.*.  *  
 
ATP13a4_Hu   EMAFS---GD DFHIKGVPAH AMVVKPCRTA SQVPVEG--- ----------  
ATP13a5_Hu   KMEDC---IV DSCKFGT-SV SNIIKPGPKA SKSPVEA--- ----------  
ATP13a3_Hu   ILEEA---TE EETALHNRIM PTVVRPPKQL LPESTPAGNQ EMELFELPAT  
ATP13a2_Hu   VLEE---EPA ADSAFG-TQV LAVMRPPLWE PQLQAMEE-- --------PP  
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zgc_136762   ELTEPENDMG HDSEFGGHRV LAVMRPPASE LLTEGNS--- --------VS  
Clustal Co    :                      :::*                            
 
ATP13a4_Hu   --IAILHQFP FSSALQRMTV IVQEMGGDRL -AFMKGAPER VASFCQPETV  
ATP13a5_Hu   --IITLCQFP FSSSLQRMSV IAQLAGENHF HVYMKGAPEM VARFCRSETV  
ATP13a3_Hu   YEIGIVRQFP FSSALQRMSV VARVLGDRKM DAYMKGAPEA IAGLCKPETV  
ATP13a2_Hu   VPVSVLHRFP FSSALQRMSV VVAWPGATQP EAYVKGSPEL VAGLCNPETV  
zgc_136762   QPVAIVRRFP FSSSLQRMSV VTVGPAEPSP VAFIKGAPEM VASFCHKESV  
Clustal Co     :  : :** ***:****:* :.   .      .::**:**  :* :*. *:*  
 
ATP13a4_Hu   PTSFVSELQI YTTQGFRVIA LAYK--KLEN ---DHHATTL TRETVESDLI  
ATP13a5_Hu   PKNFPQELRS YTVQGFRVIA LAHKTLKMGN ---LSEVEHL AREKVESELT  
ATP13a3_Hu   PVDFQNVLED FTKQGFRVIA LAHR--KLES KLTWHKVQNI SRDAIENNMD  
ATP13a2_Hu   PTDFAQMLQS YTAAGYRVVA LASK--PLPT VPSLEAAQQL TRDTVEGDLS  
zgc_136762   PSHFSHTLRE YASQGFRVLG LAYK--HLAK ETDLSTVERV E---VEKGMN  
Clustal Co   *  *   *.  ::  *:**:. ** :   : .       .  :     :*  :   
 
ATP13a4_Hu   FLGLLILENR LKEETKPVLE ELISARIRTV MITGDNLQTA ITVARKSGMV  
ATP13a5_Hu   FLGLLIMENR LKKETKLVLK ELSEARIRTV MITGDNLQTA ITVAKNSEMI  
ATP13a3_Hu   FMGLIIMQNK LKQETPAVLE DLHKANIRTV MVTGDSMLTA VSVARDCGMI  
ATP13a2_Hu   LLGLLVMRNL LKPQTTPVIQ ALRRTRIRAV MVTGDNLQTA VTVARGCGMV  
zgc_136762   FLGLLVMKNQ VKPESAEVIQ TLTLAQLRPV MVTGDNILTA VNVARVCGMV  
Clustal Co   ::**:::.*  :* ::  *::  *  :.:*.* *:***.: ** :.**: . *:  
 
ATP13a4_Hu   SESQKVILIE ANETTGSSSA SISWTLVEEK KHIMYG---N QDNYINIRDE  
ATP13a5_Hu   PPGSQVIIVE ADEPEEFVPA SVTWQLVE-N QETGPG---K KEIYMHTGNS  
ATP13a3_Hu   LPQDKVIIAE ALPPKDGKVA KINWHYADSL TQCSHPSAID PEAIPVKLVH  
ATP13a2_Hu   APQEHLIIVH ATHPERGQPA SLEFLPMESP TAVNGVK--D PDQAASYTVE  
zgc_136762   PLHEKVIFVH ASPPTAGSQA SLQFHEGEGA TATINTQ--Q TIDIPVQGQY  
Clustal Co      .::*: . *  .     * .: :   :            .             
 
ATP13a4_Hu   VSDKGREGS- YHFALTGKSF HVISQHFSSL LPKILINGTI FARMSPGQKS  
ATP13a5_Hu   STPRGEGGSC YHFAMSGKSY QVIFQHFNSL LPKILVNGTV FARMSPGQKS  
ATP13a3_Hu   DSLEDLQMTR YHFAMNGKSF SVILEHFQDL VPKLMLHGTV FARMAPDQKT  
ATP13a2_Hu   PDPRS----- RHLALSGPTF GIIVKHFPKL LPKVLVQGTV FARMAPEQKT  
zgc_136762   QSAVG----- YHLAINGMSF AALCDHFPEY LPKVLMRGTI YARMTPEQKT  
Clustal Co       .       *:*:.* ::   : .** .  :**:::.**: :***:* **:  
 
ATP13a4_Hu   SLVEEFQKLD YFVGMCGDGA NDCGALKMAH VGISLSEQEA SVASPFTSKT  
ATP13a5_Hu   SLIEEFQKLN YYVGMCGDGA NDCGALKAAH AGISLSEQEA SVASPFTSKT  
ATP13a3_Hu   QLIEALQNVD YFVGMCGDGA NDCGALKRAH GGISLSELEA SVASPFTSKT  
ATP13a2_Hu   ELVCELQKLQ YCVGMCGDGA NDCGALKAAD VGISLSQAEA SVVSPFTSSM  
zgc_136762   QLVKALQKLN YRVGMCGDGA NDCGALRAAD VGVSLSDAEA SVASPFTSKS  
Clustal Co   .*:  :*::: * ******** ******: *.  *:***: ** **.*****.   
 
ATP13a4_Hu   PNIECVPHLI KEGRAALVTS FCMFKYMALY SMIQYVGVLL LYWETNSLSN  
ATP13a5_Hu   TNIQCVPHLI REGRAALVSS FGVFKYLTMY GIIQFISALL LYWQLQLFGN  
ATP13a3_Hu   PSISCVPNLI REGRAALITS FCVFKFMALY SIIQYFSVTL LYSILSNLGD  
ATP13a2_Hu   ASIECVPMVI REGRCSLDTS FSVFKYMALY SLTQFISVLI LYTINTNLGD  
zgc_136762   DNISCVPLLI KEGRCSLVTS FSLFKYMALY SLIQFASVLI LYTEKTNLGD  
Clustal Co    .*.*** :* :***.:* :* * :**::::* .: *: .. : **     :.:  
 
ATP13a4_Hu   YQFLFQDLAI TTLIGVTMNL NGAYPKLVPF RPAGRLISPP LLLSVIFNIL  
ATP13a5_Hu   YQYLMQDVAI TLMVCLTMSS THAYPKLAPY RPAGQLLSPP LLLSIFLNSC  
ATP13a3_Hu   FQFLFIDLAI ILVVVFTMSL NPAWKELVAQ RPPSGLISGA LLFSVLSQII  
ATP13a2_Hu   LQFLAIDLVI TTTVAVLMSR TGPALVLGRV RPPGALLSVP VLSSLLLQMV  
zgc_136762   LQFLFFDLVL VTVLAILMGR GGPSNDLHPQ RPAASLLSLP VLASLLMHTV  
Clustal Co    *:*  *:.:    : . *.    .   *    **.. *:* . :* *:: :    
 
ATP13a4_Hu   LSLAMHIAGF ILVQRQPWYS -VEIHSACTV QNESISELTM SPTAPEKMES  
ATP13a5_Hu   FSCIVQISAF LYVKQQPWYC EVYQYSECFL ANQ--SNFST NVSLERNWTG  
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ATP13a3_Hu   ICIGFQSLGF FWVKQQPWYE VWHPKSDACN TTG--SGFWN SSHVDNETEL  
ATP13a2_Hu   LVTGVQLGGY FLTLAQPWFV PLNRTVAAPD NLP------- ----------  
zgc_136762   LLILAQVSGL LITMSQDWYV PLNSTRTGAA NLP------- ----------  
Clustal Co   :    :  .  : .  * *:                                    
 
ATP13a4_Hu   NSTFT----- SFENTTVWFL GTINCITVAL VFSKGKPFRQ PTYTNYIFVL  
ATP13a5_Hu   NATLIPGSIL SFETTTLWPI TTINYITVAF IFSKGKPFRK PIYTNYIFSF  
ATP13a3_Hu   DEHNIQ---- NYENTTVFFI SSFQYLIVAI AFSKGKPFRQ PCYKNYFFVF  
ATP13a2_Hu   ---------- NYENTVVFSL SSFQYLILAA AVSKGAPFRR PLYTNVPFLV  
zgc_136762   ---------- NMEDTSVFAV SGFQYIIMSV VITKGFPYKK PLYHNVLFVC  
Clustal Co              . * * :: :   :: : ::   .:** *::: * * *  *    
 
ATP13a4_Hu   VLIIQLGVCL FILFADIPEL YRRLDLLCTP VL-WRASIVI MLSLNFIVSL  
ATP13a5_Hu   LLLAALGLTI FILFSDFQVI YRGMELIPTI TS-WRVLILV VALTQFCVAF  
ATP13a3_Hu   SVIFLYIFIL FIMLYPVASV DQVLQIVCVP YQ-WRVTMLI IVLVNAFVSI  
ATP13a2_Hu   ALALLSSVLV GLVLVPG-LL QGPLALRNIT DTGFKLLLLG LVTLNFVGAF  
zgc_136762   ALVFLFALMS WLVLFRHTII HRVLSLYDIT DMSYKLLLVA IAALNFFICF  
Clustal Co    :     .    :::     :    : :        ::  ::  :   :   .:  
 
ATP13a4_Hu   VAEEAVIENR ALWMMIKRCF GYQS-KSQYR IWQRDLANDP SWPPLNQTSH  
ATP13a5_Hu   FVEDSILQNH ELWLLIKREF GFYS-KSQYR TWQKKLAEDS TWPPINRTDY  
ATP13a3_Hu   TVEESVDRWG KCCLPWALGC RKKTPKAKYM YLAQELLVDP EWPPKPQTTT  
ATP13a2_Hu   MLESVLDQCL PACLRRLR-- PKRASKKRFK QLERELAEQP -WPPLPAGPL  
zgc_136762   LLEFFIDQGA LNCLRNLR-- GKRESKKQYK RLNVQLTETP SWPPLNQPLF  
Clustal Co     *  : .      :            * ::      .*   .  ***        
 
ATP13a4_Hu   SDMPECGRGV SYSNPVFESN EEQL------ ---------- --- 
ATP13a5_Hu   SGD---GKNG FYINGGYESH EQIPKRKLKL GGQPTEQHFW ARL 
ATP13a3_Hu   EAK-----AL VKENGSCQII TIT------- ---------- --- 
ATP13a2_Hu   R--------- ---------- ---------- ---------- --- 
zgc_136762   PSQ------- ----SSVISI S--------- ---------- --- 
Clustal Co                                                   
 
Figure 8. Multiple protein sequence alignment of human ATP13a2-5 and the orthologue zgc_136762 in 
Zebrafish. The alignment was performed by ClustalX2 (“*” identical residues,“:” conserved 
substitutions,“.” semi-conserved substitutions). The yellow background highlights the E1_E2 ATPase 
domain and the green one the HAD_like domain. 
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Figure 9. Phylogenetic tree including the human ATP13a -2 to -5 and the orthologue in Zebrafish. The 
zebrafish orthologue is closer to the human ATP13a2 than to the other ATP13a3-5. ATP13a1 is a 
separate case, being closer to a different protein in Zebrafish named ATP13a. 
 
The human and Zebrafish ATP13a2 proteins are very similar in size with 1180 and 1170 
amino-acids, respectively. Phylogenetic analysis revealed that the proteins share 50% 
Identity and 69% similarity in the total sequence. Analysis of the conserved domains 
showed that the identity percentage is maintained around 50% (Figure 10). The E1-E2 
ATPase can be found in several species from bacteria to eukaryotic plasma and 
organelles. It is involved in different ions transportation across membranes using ATP 
hydrolysis for energy [89]. The haloacid dehalogenase (HAD_like) domain is found in 
proteins able to catalyze carbon or phosphoryl group transfer on several types of 
substrate, through a nucleophilic attack by an invariant active site aspartate [90]. 
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Figure 10. Side by side comparison of Human and Zebrafish ATP13a2. Both sequences share a similar 
size, 50 % homology and 69% of similarity. The conserved functional domains E1-E2 ATPase and 
HAD_like have approximately the same identity (52% and 51%, respectively) and similarity (66% and 
69%, respectively). 
 
4.2.2 Human and Zebrafish Lrrk2 display 66% similarity 
 
Concerning the human Lrrk2 protein (NP_940980.3), the blast revealed one matching 
sequence, ADJ67257. The two proteins have a similar size, 2533 bp and 2527 bp in 
zebrafish and human respectively. The alignment of the two sequences showed a 47% 
identity and 66% homology (Figures 11). All the functional domains are conserved 
between the species but with a very different homology rates, ranging from 10% to 
64% (Figure 11 and 12). 
 
D. rerio     -----MAEIE ELSIRLKKLL VRLN-LQDGK QLGTMVQIIE DLLFLSHTEH  
H. sapiens   MASGSCQGCE EDEETLKKLI VRLNNVQEGK QIETLVQILE DLLVFTYSEH  
Alignment             * * .  ****: **** :*:** *: *:***:* ***.::::**  
 
D. rerio     CVELFADQNV HVPVLLKCSE SASIK-VQQV GWSLLCRLME ICPNTLDNLA  
H. sapiens   ASKLFQGKNI HVPLLIVLDS YMRVASVQQV GWSLLCKLIE VCPGTMQSLM  
Alignment    . :** .:*: ***:*:  ..    :  **** ******:*:* :**.*::.*   
 
D. rerio     RP----MDYE FIDAHKQILK VLHEYHNKDA KMMMVALRAL ALMLKSGEIK  
H. sapiens   GPQDVGNDWE VLGVHQLILK MLTVHN-ASV NLSVIGLKTL DLLLTSGKIT  
Alignment     *     *:* .:..*: *** :*  ::  .. :: ::.*::*  *:*.**:*.  
 
D. rerio     MQVLDEEEWD VFYSILEAMK SFSDREEVQL QGCTALQPLL QTVSEYHLAE  
H. sapiens   LLILDEE-SD IFMLIFDAMH SFPANDEVQK LGCKALHVLF ERVSEEQLTE  
Alignment    : :****  * :*  *::**: **. .:***   **.**: *: : *** :*:*  
 
D. rerio     FIEKKDHEVV LNALGCFMDS ENVVLEALKV LIPLANPASN VETLMSKTVK  
H. sapiens   FVENKDYMIL LSALTNFKDE EEIVLHVLHC LHSLAIPCNN VEVLMSGNVR  
Alignment    *:*:**: :: *.**  * *. *::**..*:  * .** *..* **.*** .*:  
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D. rerio     CHSLTCRAMN TWLDSEAIQE AGCCLLWKFT SKGYYDMLVL NGVHKVAVKA  
H. sapiens   CYNIVVEAMK AFPMSERIQE VSCCLLHRLT LGNFFNILVL NEVHEFVVKA  
Alignment    *:.:. .**: ::  ** *** ..**** ::*   .::::*** * **:..***  
 
D. rerio     CVSYPDNAIL QTAALSCLSA LAECIVQNGG LDEEWNEEDE EEQKVLVKKE  
H. sapiens   VQQYPENAAL QISALSCLAL LTETIFLNQD LEEKNENQEN DDE-------  
Alignment      .**:** * * :*****:  *:* *. * . *:*: ::::: :::         
 
D. rerio     AAQAEEMLIW REACYTAFER HAEDVKVQEA ACWTLNSLLL HCN--TSNHV  
H. sapiens   --GEEDKLFW LEACYKALTW HRKNKHVQEA ACWALNNLLM YQNSLHEKIG  
Alignment        *: *:*  ****.*:   * :: :**** ***:**.**: : *   .:    
 
D. rerio     ELEGRPPLHT LIMAAMLLHS SSVKVFQAAS STLRTLIQRH CRIRSPLLSN  
H. sapiens   DEDGHFPAHR EVMLSMLMHS SSKEVFQASA NALSTLLEQN VNFRKILLSK  
Alignment    : :*: * *   :* :**:** ** :****:: .:* **::::  .:*. ***:  
 
D. rerio     GIHFNIVELM RKHPNSSAVC ESACKLIHTL FQGARASLDD GFLILSQILI  
H. sapiens   GIHLNVLELM QKHIHSPEVA ESGCKMLNHL FEGSNTSLDI MAAVVPKILT  
Alignment    ***:*::*** :** :*. *. **.**::: * *:*:.:***     ::.:**   
 
D. rerio     ALKTHTFLPE VQLEGLRASL VLLNPDRSLR EHGVSVADPD MVDVSLQVLK  
H. sapiens   VMKRHETSLP VQLEALRAIL HFIVPGMPEE SR-----EDT EFHHKLNMVK  
Alignment    .:* *      ****.*** *  :: *. . . .:     :    .. .*:::*  
 
D. rerio     NQCVLEGAHT VYLQALNRFI SSESIQECGL GVLAALADSS GAVDLMCQQG  
H. sapiens   KQCFKNDIHK LVLAALNRFI GNPGIQKCGL KVISSIVHFP DALEMLSLEG  
Alignment    :**. :. *. : * ****** .. .**:***  *::::.. . .*::::. :*  
 
D. rerio     AIDTVLHTLQ MFPQERDIHY WGLSLLFHLI SKKKLSRMMV PVLASVLVSS  
H. sapiens   AMDSVLHTLQ MYPDDQEIQC LGLSLIGYLI TKKNVFIGTG HLLAKILVSS  
Alignment    *:*:****** *:*::::*:   ****: :** :**::       :**.:****  
 
D. rerio     VRKHKEDSVM LLKGLQVVWK LLDTCSSAAV WLQKEAFEKE IFQILRENTA  
H. sapiens   LYRFKDVAEI QTKGFQTILA ILKLSASFSK LLVHHSFDLV IFHQMSSNIM  
Alignment    : :.*: : :   **:*.:   :*. .:* :   * :.:*:   **: : .*    
 
D. rerio     DQRRDPLQGM SCLCLSKMVM DGEILYALLE RACEDGDVDM AECLIQLGAD  
H. sapiens   EQKDQQFLNL CCKCFAKVAM DDYLKNVMLE RACDQNNSIM VECLLLLGAD  
Alignment    :*: : : .: .* *::*:.* *. :  .:** ***::.:  * .***: ****  
 
D. rerio     VNKKTKSDSL LYQACDRGAP LSLLELLVSS GVHEQHLRGA LSVCVRRSDD  
H. sapiens   ANQAKEGSSL ICQVCEKESS PKLVELLLNS GSREQDVRKA LTISIGKGDS  
Alignment    .*: .:..** : *.*:: :.  .*:***:.* * :**.:* * *::.: :.*.  
 
D. rerio     PAVTLILRRL GLDHTNSALC LGSVRIGHMK ASWISALLSE RRSQSTNTHY  
H. sapiens   QIISLLLRRL ALDVANNSIC LGGFCIGKVE PSWLGPLFPD KTSNLR--KQ  
Alignment      ::*:**** .** :*.::* **.. **::: .**:..*:.: : *:    :   
 
D. rerio     SSKGQRLARQ ISQLQRKKGI VGVSRLSSDV STSGYFTDEE SDDSHIS--L  
H. sapiens   TNIASTLARM VIRYQMKSAV EEGTASGSDG NFSEDVLSKF DEWTFIPDSS  
Alignment    :. .. ***  : : * *..:    :  .**  . *  . .:  .: :.*.     
 
D. rerio     EDSLVFMFDE LESDGSDGPP HGFMLISDSP EVSRRPVWRR RSHSRRTSSE  
H. sapiens   MDSVFAQSDD LDSEGSEGS- --FLVKKKSN SISVGEFYRD AVLQRCSPNL  
Alignment     **:.   *: *:*:**:*.    *:: ..*  .:*   .:*     .* :..   
 
D. rerio     GYHG------ --EADPSVPV QKHANSHNSR GQG------- FSESFSSPVV  
H. sapiens   QRHSNSLGPI FDHEDLLKRK RKILSSDDSL RSSKLQSHMR HSDSISS-LA  
Alignment      *.         . *      :*  .*.:*   ..        .*:*:** :.  
 
D. rerio     LDKDPVRLLD LSGNELNDLS CLTDLNSLKK PIENLHRLDL SGNNLSQFPS  
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H. sapiens   SEREYITSLD LSANELRDID ALSQKCCISV HLEHLEKLEL HQNALTSFPQ  
Alignment     ::: :  ** **.***.*:. .*::  .:.   :*:*.:*:*   * *:.**.  
 
D. rerio     ILCQSLRSLT RLDLQGNHLQ CLPSELLSLP ALHTLNVSRN CIGPLLQLEP  
H. sapiens   QLCETLKSLT HLDLHSNKFT SFPSYLLKMS CIANLDVSRN DIGPSVVLDP  
Alignment     **::*:*** :***:.*::  .:** **.:. .: .*:****  *** : *:*  
 
D. rerio     GVCSPALRRL NLSFNQITVC PFQLRSATQR LEELSLEGNQ ISELSLPLCL  
H. sapiens   TVKCPTLKQF NLSYNQLSFV PENLTDVVEK LEQLILEGNK ISGICSPLRL  
Alignment     * .*:*::: ***:**::.  * :* ...:: **:* ****: ** :. ** *  
 
D. rerio     AELKVLDVSK NQVKIVSDNF LAECLKMETF IASVNQISSL PHLPSKITTV  
H. sapiens   KELKILNLSK NHISSLSENF LEACPKVESF SARMNFLAAM PFLPPSMTIL  
Alignment     ***:*::** *::. :*:** *  * *:*:*  * :* :::: *.**..:* :  
 
D. rerio     KLSHNTFTSV PEIVINLPCL RSVDMRNNSV GVLPGPSVWL SVNLRELMFS  
H. sapiens   KLSQNKFSCI PEAILNLPHL RSLDMSSNDI QYLPGPAHWK SLNLRELLFS  
Alignment    ***:*.*:.: ** ::*** * **:** .*.:   ****: *  *:*****:**  
 
D. rerio     HNLISALDLS GPVYKWARLE KLHLSFNRLT EIPPQIGMLE DLTSLDVSHN  
H. sapiens   HNQISILDLS EKAYLWSRVE KLHLSHNKLK EIPPEIGCLE NLTSLDVSYN  
Alignment    ** ** ****   .* *:*:* *****.*:*. ****:** ** :*******:*  
 
D. rerio     EGLRSFPDEM GKLVHLWDLP LDGLQLQLDL KHIGSKTKDI IRFLQQRLKK  
H. sapiens   LELRSFPNEM GKLSKIWDLP LDELHLNFDF KHIGCKAKDI IRFLQQRLKK  
Alignment      *****:** *** ::**** ** *:*::*: ****.*:*** **********  
 
D. rerio     AVPYHRMKLM VLGGTGSGKS SLIQQLMRLR RS---QWRSD PGVSIRDWPV  
H. sapiens   AVPYNRMKLM IVGNTGSGKT TLLQQLMKTK KSDLGMQSAT VGIDVKDWPI  
Alignment    ****:***** ::*.*****: :*:****: : :*      :   *:.::***:  
 
D. rerio     RSKDKR--NM MLNVWEFSGG EECSGIHPHF MSSRAVYLVL YDLSKGASEI  
H. sapiens   QIRDKRKRDL VLNVWDFAGR EEFYSTHPHF MTQRALYLAV YDLSKGQAEV  
Alignment    : :***  :: :****:*:*  **  . **** *:.**:**.: ****** :*:  
 
D. rerio     HSIKPWLFNI KAVAGQCPVI VVGTHADLCE ERHLQECLLK LQKELQSQPG  
H. sapiens   DAMKPWLFNI KARASSSPVI LVGTHLDVSD EKQRKACMSK ITKELLNKRG  
Alignment    .::******* ** *...*** :**** *:.: *:: : *: * : *** .: *  
 
D. rerio     FPAIRENHVL SACEESESLG RLRKAIYREL IGFKIQGQPV MGQLVPDCYV  
H. sapiens   FPAIRDYHFV NATEESDALA KLRKTIINES LNFKIRDQLV VGQLIPDCYV  
Alignment    *****: *.: .* ***::*. :***:* .*  :.***:.* * :***:*****  
 
D. rerio     ELEKRLLQER SCAPADFPVL RHSRLMEILQ ETQLQLEEGE LPHAIHFLSE  
H. sapiens   ELEKIILSER KNVPIEFPVI DRKRLLQLVR ENQLQLDENE LPHAVHFLNE  
Alignment    **** :*.** . .* :***:  :.**::::: *.****:*.* ****:***.*  
 
D. rerio     AGVLLHFDDP VLQLKDLYFI DPQWFCRIIS QTLSLKSSGP WDSTKGVVQR  
H. sapiens   SGVLLHFQDP ALQLSDLYFV EPKWLCKIMA QILTVKVEGC PKHPKGIISR  
Alignment    :******:** .***.****: :*:*:*:*:: * *::* .*   . .**::.*  
 
D. rerio     STVEKFVEKS RCFPKDHMIQ YFKLLEKFQI ALPFDHDQLL IPSSLSDHRP  
H. sapiens   RDVEKFLSKK RKFPKNYMSQ YFKLLEKFQI ALPIGEEYLL VPSSLSDHRP  
Alignment      ****:.*. * ***::* * ********** ***:..: ** :*********  
 
D. rerio     VIELPHCENS EVIIRLYEMP YFPMGYWPRQ ISRLLEVSAF LLYGREKALK  
H. sapiens   VIELPHCENS EIIIRLYEMP YFPMGFWSRL INRLLEISPY MLSGRERALR  
Alignment    ********** *:******** *****:*.*  *.****:*.: :* ***:**:  
 
D. rerio     PNRIYWRKGI YLSWSAEAYC LVEALTLEEN PASFIKITVP CSRKGRVLFG  
H. sapiens   PNRMYWRQGI YLNWSPEAYC LVGSEVLDNH PESFLKITVP SCRKGCILLG  
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Alignment    ***:***:** **.**.**** ** : .*::: * **:***** ..*** :*:*  
 
D. rerio     QVVDHIDSLL EEWFPGLLTT DIHGTGETLL KKWALYSFSD GQNCQKMLLE  
H. sapiens   QVVDHIDSLM EEWFPGLLEI DICGEGETLL KKWALYSFND GEEHQKILLD  
Alignment    *********: ********   ** * ***** ********.* *:: **:**:  
 
D. rerio     DLLSNTNADG LLVNPEDPSC TLPISQISPD LVLSDQPSST ILDPEQLEME  
H. sapiens   DLMKKAEEGD LLVNPDQPRL TIPISQIAPD LILADLPRNI MLNNDELEFE  
Alignment    **:.::: .. *****::*   *:*****:** *:*:* * .  :*: ::**:*  
 
D. rerio     LTAEYMLGDG GFGSVYKAVY KNEEVAVKIF NKHASALYVH RLVRQELAVL  
H. sapiens   QAPEFLLGDG SFGSVYRAAY EGEEVAVKIF NKHTS----L RLLRQELVVL  
Alignment     :.*::**** .*****:*.* :.******** ***:*      **:****.**  
 
D. rerio     GRLCHPSLVG LLAAGCNPHI LVMELAPYGS LDSLFERENG SLSRKLQHRI  
H. sapiens   CHLHHPSLIS LLAAGIRPRM LVMELASKGS LDRLLQQDKA SLTRTLQHRI  
Alignment     :* ****:. ***** .*:: ******. ** ** *:::::. **:*.*****  
 
D. rerio     ALHVADGLKY LHSSMIIYRD LKPHNVLLFN LKTDAEIVAK ITDYGIAQYC  
H. sapiens   ALHVADGLRY LHSAMIIYRD LKPHNVLLFT LYPNAAIIAK IADYGIAQYC  
Alignment    ********:* ***:****** *********. * .:* *:** *:********  
 
D. rerio     CSMGVRSSEG TPGFRAPEVA RGNVIYNVQA DVYSFGLLLY DLLTYGERIS  
H. sapiens   CRMGIKTSEG TPGFRAPEVA RGNVIYNQQA DVYSFGLLLY DILTTGGRIV  
Alignment    * **:::*** ********** ******* ** ********** *:** * **   
 
D. rerio     DGMKFPSEFD EVAVQGKLPD PVKDYGCSPW PEIESLMREC MRENPQDRPT  
H. sapiens   EGLKFPNEFD ELEIQGKLPD PVKEYGCAPW PMVEKLIKQC LKENPQERPT  
Alignment    :*:***.*** *: :****** ***:***:** * :*.*:::* ::****:***  
 
D. rerio     SAQVFDRLNS AEMLCLTREL NVVGFPGECF VVSNSGGAAN GGKNPHVWIG  
H. sapiens   SAQVFDILNS AELVCLTRRI LLP----KNV IVECMVATHH NSRNASIWLG  
Alignment    ****** *** **::****.:  :     : . :*.   .: : ..:*. :*:*  
 
D. rerio     GGSSSQKLGC VTAVDLETGG SLNQELDRSP ILCMVIIRAA DSCSDWLVAG  
H. sapiens   CGHTDR--GQ LSFLDLNTEG YTSEEVADSR ILCLALVHLP VEKESWIVSG  
Alignment     * :.:  *  :: :**:* *   .:*:  *  ***:.::: .  . ..*:*:*  
 
D. rerio     SESGSLSIMD TINAKVLHRL KSVKDSVTSL YFHTELQHRC LKSYLLVGTA  
H. sapiens   TQSGTLLVIN TEDGKKRHTL EKMTDSVTCL YCNSFSKQSK QKNFLLVGTA  
Alignment    ::**:* ::: * :.*  * * :.:.****.* * ::  ::    *.:******  
 
D. rerio     DGTLVIYEDS ALKLENGGPV KTLEVGDVNT PLMCLGPSSH PQERRSLWAA  
H. sapiens   DGKLAIFEDK TVKLKGAAPL KILNIGNVST PLMCLSESTN STERNVMWGG  
Alignment    **.*.*:**. ::**:...*: * *::*:*.* *****. *:: . **. :*..  
 
D. rerio     CGTRIILFTV EFDVCRSIDT KPKPLFPLQA RVSGEACISR LAVDKHVYVS  
H. sapiens   CGTKIFSFSN DFTIQKLIET RTSQLFSYAA FS--DSNIIT VVVDTALYIA  
Alignment    ***:*: *:  :* : : *:* :.. **.  *     :: *   :.**. :*::  
 
D. rerio     KTGGHTVEVW DKKTERMVNL IDCMQLLGLS STRKPKVHSE DQSRPMVPSL  
H. sapiens   KQNSPVVEVW DKKTEKLCGL IDCVHFLREV MVKE----NK ESKHKMSYSG  
Alignment    * .. .**** *****:: .* ***:::*     .::    .: :..: *  *   
 
D. rerio     VVKALLVQHS GTLWIGTRAG HILLVEVSSC HLLQTINPHC HSIRCMSSIL  
H. sapiens   RVKTLCLQKN TALWIGTGGG HILLLDLSTR RLIRVIYNFC NSVRVMMTAQ  
Alignment     **:* :*:.  :***** .* ****:::*:  :*::.*  .* :*:* * :    
 
D. rerio     LDTLNRKNVI LVLGRRQRIH LEQLKTQSGE DSVLTLWSSS LPLEARDLMR  
H. sapiens   LGSL--KNVM LVLG-YNRKN TEGTQKQKEI QSCLTVWDIN LPHEVQNLEK  
Alignment    *.:*  ***: ****  :* :  *  :.*.   :* **:*. . ** *.::* :  
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D. rerio     HCELRDKTTR RMRETLLN 
H. sapiens   HIEVRKELAE KMRRTSVE 
Alignment    * *:*.: :. :**.* :: 
Figure 11. Multiple protein sequence alignment of Human and Zebrafish Lrrk2 orthologues. The 
alignment was performed by ClustalX2 (“*” identical residues, “:” conserved substitutions, “.” semi-
conserved substitutions). In yellow background is the Ankyrin domain in both sequences, the Leucine 
rich repeat domain in green background, ROC domain in Light blue. In grey background, the COR domain 
which is the domain with the highest homology between the two species. The Kinase domain is in dark 
blue and in red the WD40 domain. 
 
 
The simple modular architecture research tool (SMART) analysis revealed that all the 
functional domains in Human Lrrk2 are also conserved in Zebrafish. The inter-species 
homology of the functional domains is different from domain to domain with the 
Ankyrin and WD40 ones having the lowest homology and the COR and Kinase domain 
the highest (Figure 12). 
 
 
 
 
 
 
Figure 12. Human and Zebrafish Lrrk2 proteins. The two proteins have identical sizes and share the 
same functional domains with different homology between them. Homologies over 50% are found in 
four domains: LRR, ROC, COR and Kinase. The other two domains share very small homology with 15% 
for the Ankyrin domain and 10% for the WD40 domain. 
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4.2.3 Functional Domain of SNCAIP is 93% similar between species 
 
Synphilin-1 (NP_005451.2) is the product of the gene SNCAIP. The blast analysis 
revealed one sequence in the Zebrafish genome with high homology, zgc:172291. The 
sequence from zebrafish is smaller (738 aa) when compared with the human one (938 
aa) with 44% identity and 59% similiarity (Figure 13). The proteins share the same 
functional domain (Ankyrin) 78% identical between them and with a similarity of 93% 
(Figure 14). The Ankyrin repeats are responsible for protein-protein interactions and 
can be found in several types of proteins including cytoskeletal organizers and cell 
development and differentiation proteins (review at [91]). 
 
D. rerio     MDVPEYLDLD EIDFTDDLPY SS---KSIPE LCRRHDGQND ERQALAINWP  
H. sapiens   MEAPEYLDLD EIDFSDDISY SVTSLKTIPE LCRRCDTQNE DRSVSSSSWN  
Alignment    *:.******* ****:**:.* *    *:*** **** * **: :*.. : .*   
 
D. rerio     RSAASHSGAG LKPTGIADVY SKFRPVKRVS PLKHQPEETQ TQTETEGKSS  
H. sapiens   CGISTLITNT QKPTGIADVY SKFRPVKRVS PLKHQPETLE NNESDDQKNQ  
Alignment     . ::       ********* ********** *******  : .: . : *..  
 
D. rerio     ---------E TDTPSGKEEP SKSRGLIN-- ------QALF GELEHYDLDM  
H. sapiens   KVVEYQKGGE SDLGPQPQEL GPGDGVGGPP GKSSEPSTSL GELEHYDLDM  
Alignment             * :*  .  :*  . . *: .         .: : **********  
 
D. rerio     DEILDVPYIK CTQQAATLPR APS------- -------AGN THTLVHSESL  
H. sapiens   DEILDVPYIK SSQQLASFTK VTSEKRILGL CTTINGLSGK ACSTGSSESS  
Alignment    ********** .:** *::.: ..*               :*: : :   ***   
 
D. rerio     SS-GTQFCVL SPV----MRK SKSADLRAQS LGFENTHEQI PDSKTG----  
H. sapiens   SSNMAPFCVL SPVKSPHLRK ASAVIHDQHK LSTEETEISP PLVKCGSAYE  
Alignment    **  : **** ***    :** :.:.    :. *. *:*. .  *  * *      
 
D. rerio     ---------- ---------- ---------- -------ADG GHASRKQARG  
H. sapiens   PENQSKDFLN KTFSDPHGRK VEKTTPDCQL RAFHLQSSAA ESKPEEQVSG  
Alignment                                            : .    ..:*. *  
 
D. rerio     VSR------- EVDEEAKKSQ NILNIVRDGQ ISLLPHFAAE NLELIRDEDG  
H. sapiens   LNRTSSQGPE ERSEYLKKVK SILNIVKEGQ ISLLPHLAAD NLDKIHDENG  
Alignment    :.*        * .*  ** : .*****::** ******:**: **: *:**:*  
 
D. rerio     NNLLHVSAAQ GHTDCLQHLT SLMGEDCLNE RNKQQLTPAG LSVRNGHLEC  
H. sapiens   NNLLHIAASQ GHAECLQHLT SLMGEDCLNE RNTEKLTPAG LAIKNGQLEC  
Alignment    *****::*:* **::****** ********** **.::***** *:::**:***  
 
D. rerio     VRWMVSETEA IAELSCTREH PSLIHYAARY GQERVLLWLL QFMQEQAISL  
H. sapiens   VRWMVSETEA IAELSCSKDF PSLIHYAGCY GQEKILLWLL QFMQEQGISL  
Alignment    ********** ******:::. *******. * ***::***** ******.***  
 
D. rerio     DEQDQNGNSA VHVAAQFGHL GCLQTLVEYG SNVTVQNQQC ERASQCAERQ  
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H. sapiens   DEVDQDGNSA VHVASQHGYL GCIQTLVEYG ANVTMQNHAG EKPSQSAERQ  
Alignment    ** **:**** ****:*.*:* **:******* :***:**:   *:.**.****  
 
D. rerio     GHTTCSRYLV VVETCMSLAS QVVKLTKQLH EQTTARVALQ NQLQLLLQTQ  
H. sapiens   GHTLCSRYLV VVETCMSLAS QVVKLTKQLK EQTVERVTLQ NQLQQFLEAQ  
Alignment    *** ****** ********** *********: ***. **:** **** :*::*  
 
D. rerio     EPNGR--PPS PSCRVPPS-- -------DSW PEMTLTAEVA PENGQWVL--  
H. sapiens   KSEGKSLPSS PSSPSSPASR KSQWKSPDAD DDSVAKSKPG VQEGIQVLGS  
Alignment    :.:*:  *.* **.  .*:          *:   : . .:: .  ::*  **    
 
D. rerio     ---------K QKHTETDGVM RKLLTKDAAE RTHPRDTHDA GAESGAGPGA  
H. sapiens   LSASSRARPK AKDEDSDKIL RQLLGKEISE NVCTQEKLSL EFQDAQASSR  
Alignment             *  *. ::* :: *:** *: :* .. .::. .    :.. ...   
 
D. rerio     GPMKRLGVGE RRELKLARLK QIMQRSLSES DGDVYPPDE- ----TKHMSR  
H. sapiens   NSKKIP--LE KRELKLARLR QLMQRSLSES DTDSNNSEDP KTTPVRKADR  
Alignment    .. *     * :********: *:******** * *   .::      .:: .*  
 
D. rerio     PTQLPIPEAE E--------- ---PKNTHSS SERKLSFTHR TSKSVDACNP  
H. sapiens   PRPQPIVESV ESMDSAESLH LMIKKHTLAS GGRRFPFSIK ASKSLDGHSP  
Alignment    *   ** *:  *              *:* :* . *::.*: : :***:*. .*  
 
D. rerio     SPSSDQSDPE TR-------- ---------- ------TEAG DKVTTSPKSA  
H. sapiens   SPTSESSEPD LESQYPGSGS IPPNQPSGDP QQPSPDSTAA QKVATSPKSA  
Alignment    **:*:.*:*:  .                          : *. :**:******  
 
D. rerio     LKSPSSRRKT SQNLKLRVTF DEPP------ ------RKDG AAGDTKAPST  
H. sapiens   LKSPSSKRRT SQNLKLRVTF EEPVVQMEQP SLELNGEKDK DKGRTLQRTS  
Alignment    ******:*:* ********** :**              .**    * *   ::  
 
D. rerio     KE-------K RPFGAFRSIM ETLSGNQNNN NSNSSSSNAQ -------SPG  
H. sapiens   TSNESGDQLK RPFGAFRSIM ETLSGNQNNN NNYQAANQLK TSTLPLTSLG  
Alignment    ..       * ********** ********** *. .::.: :        * *  
 
D. rerio     KHTGKKSKSK TSAV------ - 
H. sapiens   RKTDAKGNPA SSASKGKNKA A 
Alignment    ::*. *.:.  :**          
 
Figure 13. Alignment of the Human and Zebrafish Synphilin-1 sequences. The alignment was 
performed by ClustalX2 (“*” identical residues, “:” conserved substitutions, “.” semi-conserved 
substitutions). In yellow background is the only functional domain of Synphilin-1: Ankyrin. 
 
 
 
 
 
 
Figure 14. Human and Zebrafish synphilin-1. Although the total protein sequence is only 44% 
homologue between species, the functional domain shares 78% identity and 93% similarity. 
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4.2.4 Glucocerebrosidase in zebrafish has the same functional domain 
found in humans 
 
The blast of Glucocerebrosidase sequence (NP_001005750.1) against the fish model 
genome showed a highly homologous sequence in zebrafish, LOC559072. Both 
sequences share 54% identity, 68% similarity, and similar sizes, 536 in Human GBA and 
518 in Zebrafish (Figure 15). The functional domain that represents the majority of the 
sequence is 57% identical (Figure 16).  
 
 
D. rerio     ---------- -MRETALFIL LAGIIT---- ---TARADSK DGCLALNFGH  
H. sapiens   MEFSSPSREE CPKPLSRVSI MAGSLTGLLL LQAVSWASGA RPCIPKSFGY  
Aligment                  :  : . : :** :*        .: *..    *:. .**:  
 
D. rerio     GSVVCVCNAT YCDSLGRTVL PDAGQFLSYV SNKAGSRLME SQGQFQKNST  
H. sapiens   SSVVCVCNAT YCDSFDPPTF PALGTFSRYE STRSGRRMEL SMGPIQANHT  
Aligment     .********* ****:. ..: *  * *  *  *.::* *:   * * :* * *  
 
D. rerio     GAALRITLNP SQKFQHIKGF GGAMTDAAAI NILSLSSGAQ DQLLRQYFST  
H. sapiens   GTGLLLTLQP EQKFQKVKGF GGAMTDAAAL NILALSPPAQ NLLLKSYFSE  
Aligment     *:.* :**:* .****::*** *********: ***:**. ** : **:.***   
 
D. rerio     DGIEYRFVRV PVASCDFSTR LYTYADTPED YDLQNFTLAK EDVHMKIPLL  
H. sapiens   EGIGYNIIRV PMASCDFSIR TYTYADTPDD FQLHNFSLPE EDTKLKIPLI  
Aligment     :** *.::** *:****** *  *******:* ::*:**:*.: **.::****:  
 
D. rerio     QRAQALSAQP LYLFASAWSA PAWLKTNGAL IGKGSLKGKP GGKEHKTWAQ  
H. sapiens   HRALQLAQRP VSLLASPWTS PTWLKTNGAV NGKGSLKGQP GDIYHQTWAR  
Aligment     :**  *: :* : *:**.*:: *:*******:  *******:* *.  *:***:  
 
D. rerio     YYIRFLEEYR KYNLSFWGLT SGNEPTAGEM TNYSFQALGF TPETQRDWIA  
H. sapiens   YFVKFLDAYA EHKLQFWAVT AENEPSAGLL SGYPFQCLGF TPEHQRDFIA  
Aligment     *:::**: *  :::*.**.:* : ***:** : :.*.**.*** *** ***:**  
 
D. rerio     LDLGPALHSS SFSKTQLMIL DDNRLMLPHW AKVVLSDIKA ARYVHGIGVH  
H. sapiens   RDLGPTLANS THHNVRLLML DDQRLLLPHW AKVVLTDPEA AKYVHGIAVH  
Aligment      ****:* .* :. :.:*::* **:**:**** *****:* :* *:*****.**  
 
D. rerio     WYFDRLVPPD VTLTSTHHLY PDYFLFATEA CAGWSPVDRG VRLGSWDRAE  
H. sapiens   WYLDFLAPAK ATLGETHRLF PNTMLFASEA CVGSKFWEQS VRLGSWDRGM  
Aligment     **:* *.*.. .** .**:*: *: :***:** *.* .  ::. ********.   
 
D. rerio     DYAHDIIQDL NNYVTGWTDW NLALNQDGGP NWVKNFVDSP IIVDPSKDIF  
H. sapiens   QYSHSIITNL LYHVVGWTDW NLALNPEGGP NWVRNFVDSP IIVDITKDTF  
Aligment     :*:*.** :*   :*.***** ***** :*** ***:****** **** :** *  
 
D. rerio     YKQPTFYSMA HFSKFLWEES QRVGVSFSQQ TSLEMSAFIR PDASAVLIIL  
H. sapiens   YKQPMFYHLG HFSKFIPEGS QRVGLVASQK NDLDAVALMH PDGSAVVVVL  
Aligment     **** ** :. *****: * * ****:  **: ..*:  *::: **.***:::*  
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D. rerio     NRSEEEVPFE VWDQTVGFLP GSAPPHSILT LLWNRQ 
H. sapiens   NRSSKDVPLT IKDPAVGFLE TISPGYSIHT YLWRRQ 
Aligment     ***.::**:  : * :****    :* :** *  **.** 
 
Figure 15. Multiple protein sequence alignment of Human GBA and its orthologue in Zebrafish. The 
alignment was performed by ClustalX2 (“*” identical residues, “:” conserved substitutions, “.” semi-
conserved substitutions). In yellow background is the Glyco domain that is common in both sequences. 
. 
 
Figure 16. Human and Zebrafish GBA protein sequence homology and functional domain. The proteins 
share the same size and are 54% identical. The functional domain represents the majority of the protein 
sequence and, therefore, the homology is very similar to the total protein sequence, 57%. 
 
 
4.3 ATP13a2 is expressed during Zebrafish embryonic development 
 
Using the WISH technique, a spatial analysis of ATP13a2 was performed. Embryos at 
different stages of development were probed: 12, 24, 48, 72 hpf and 6 dpf. It is 
possible to see that the gene expression is more ubiquitous in the early development 
stages, 12hpf, while with ageing it localizes specifically in the embryo’s brain (Figure 17 
A – E). The sense probe, which works as a control probe, didn’t provide any signal 
(Figure 17: F and G).  
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Figure 17. ATP13a2 expression during embryonic development. Gene expression is marked in purple as 
a result of a reaction with the antibody of digoxigenine. A) at 12hpf, ATP13a2 is found throughout the 
embryo; B) The expression, at 24hpf, is only found in the upper part of the embryo, especially in the 
brain area; C) Although the expression is more diffuse, a strong signal in the brain at 48 hpf is still 
observed. The expression is very similar at 72 hpf D) and 6 dpf E) being restricted to the brain of the 
embryo, more specifically at the front end. F) and G) No expression is observed with the sense probe in 
embryos with 12 hpf and 48 hpf, for example. Scale bar: 100µm. 
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5. Discussion 
 
5.1 Transgenic zebrafish as a model of PD 
 
Three tg lines were successfully generated: THrat:IRES:GFP, THrat:a-syn:IRES:GFP and 
THzeb:GFP. Currently, these lines are in different stages of development with the 
TH:IRES:GFP and TH:a-syn:IRES:GFP in process of development. The fish injected with 
the construct THzeb:GFP were already crossed with wt zebrafish and positive F1 
generation was obtained. Two of them, THrat:IRES:GFP and THzeb:GFP, will be used as 
control lines:  the first will be a control for the THrat:a-syn:IRES:GFP, specially for 
behavior analysis, to ensure that any result is only due to the expression of a-syn and 
not from the micro-injection process. 
Other model’s goal is to study the advantage/disadvantage of using the IRES sequence. 
The THzeb:GFP will be compared with THzeb:IRES:GFP, which is under development, 
thus it will be possible to understand the effect of IRES. If IRES is proven to negatively 
modulate the expression of the gene throughout the fish development, it will be 
necessary to find new alternatives. The simplest one would be the fusion of a-syn with 
GFP, however it is controversial if the normal role of a-syn is maintained and, 
therefore, other alternatives must be found. 
Different concentrations of the co-injection tranposase mRNA and DNA concentrations 
were investigated with the THrat:IRES:GFP construct. With initial concentrations of 
30ng/µl DNA: 25ng/µl mRNA transposase no strong fluorescence was detected (Figure 
6 A-B) when compared to the control (non-injected) Zebrafish (Figure6 I-J). Higher 
concentrations were tested and the best one used to generate the transgenic lines was 
80ng/µl DNA: 50 ng/µl mRNA transposase. With this concentration it is possible to see 
visible expression of the construct as seen in Figure 6 C-D). The pattern of expression, 
being mostly present in the zebrafish eye, is in accordance with the expression seen by 
Gao et al [92].This concentration is the maximum possible concentration since higher 
ones have induced morphological abnormalities in the fish. 
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Concerning the THzeb:GFP construct, lower concentrations were sufficient to generate 
the founder fish (Figure 6 G-H). 
To understand the pattern and levels of a-syn expression and compare them with the 
fluorescence analysis results, behavior tests and molecular analysis by western blot 
and immunohistochemistry will be investigated in the F1 generation.  
So far, no molecular tests will be performed in the founder fish for two main reasons. 
The first is the possibility to obtain false positives. Western-blot analysis would 
indicate the a-syn levels, however the construct might only be transiently expressed 
and not inserted in the genome. If a-syn is found in the next generations, it is ensured 
that our gene of study is integrated in the zebrafish genome and therefore a transgenic 
line has been generated. The second reason relates to the number of founder fish. The 
efficiency of the Tol2 technique is between 30% to 70% and from those remaining 
embryos only the ones with the higher fluorescence were chosen to become founder 
fish for the lines. 
 
5.2 PD  genes in Zebrafish 
 
In agreement with previous studies [68-72], the studied genes revealed high homology 
with the human orthologues. For ATP13a2-5, Zebrafish has only one matching 
sequence. Through phylogenetic and functional domains analysis, it is possible to 
determine that the hit, zgc:136762 is more identical to ATP13a2 than the other 
ATP13ases human family members and therefore might be considered as zebrafish 
ATP13a2. Both functional domains are conserved meaning that the function of the 
protein might be conserved in the two species. The WISH experiments suggested that 
in the early stages of development, 12 hpf, ATP13a2 is present throughout the 
embryo’s body (Figure 17.A), probably due to maternal heritance rather than 
embryonic expression. The expression pattern during development is more restrained 
in the upper part of the body after 24 hpf (Figure 17.B), and embryos older than 48 hpf 
show a specific expression in the brain, especially in the frontal area (Figure 17.C-E). 
Lrrk2 is one of the most important protein linked to PD. Due to its size, it has been one 
of the most difficult proteins to study in animal models. The sequence matching to 
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human Lrrk2 is a 2533 amino-acid protein sharing the same functional domains. The 
homology between the different domains is very variable ranging from 10 in the WD40 
domain to 64% in the kinase domain. In agreement with recent results, the deletion of 
the WD40 domain was also shown to trigger a Parkinsonian-like behavior in Zebrafish 
[93]. 
Zebrafish has also a Synphilin-1 homologue and is in this protein where the homology 
between the two species is more remarkable. Although the homology of the total 
sequence is 44%, the functional domain is conserved between the two species with 
78% identity and 93% of similarity. Synphilin-1 is known to interact with a-syn and 
might contribute to the formation of protein aggregates [94], suggesting that, although 
a-syn has not yet been described in zebrafish, it may be present in the zebrafish 
genome similarly to other fish species [95, 96]. The continuous work to sequence the 
full genome of Zebrafish will, probably, allow the discovery of a-syn gene. It would also 
be interesting to analyze the role of synphilin-1 in zebrafish and develop an in vivo 
model to study protein aggregation, commonly reported in PD patients.  
Glucocerebrosidase is also present in the zebrafish genome. The percentages of 
homology are in agreement with the average of values presented by the other studied 
proteins, with 54% and the similarity of 68%. Both human and zebrafish have the same 
functional domain, Glyco_Hydro_30, which is responsible for the regulation of beta-
glucocerebrosidase. Moreover, the values of identity and similarity are identical to the 
whole sequence values, 57% and 68% respectively. 
The high homology of all PD-related proteins between Zebrafish and Human (Table 2) a 
homology that is present also in their conserved domains (Table 3) makes zebrafish a 
good animal to study the disease.  
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Table 2. Identity and Similarity between human PD genes and Zebrafish 
Gene  Identity Similarity 
Parkin 62%  75%  
Pink – 1  54%  (67%)*  
DJ-1  83%  89%  
UCHL-1  (66%)*  79%  
ATP13a2  50%  69%  
Lrrk2  41%  57%  
Synphilin – 1  44%  59%  
Glucocerebrosidase 54%  68%  
a-syn Nothing Nothing 
Table 3- Identity and similarity of the studied genes Functional Domains  
Gene Functional Domain Identity Similarity 
ATP13a2 E1_E2 ATPase 53% 66% 
HAD_like 51% 69% 
 
 
 
 
LRR2K2 
Ankyrin 15% 24% 
LRR 52% 72% 
ROC 51% 76% 
COR 63% 79% 
Mapkkk 64% 75% 
WD40 10% 15% 
Synphilin -1 Ankyrin 78% 93% 
Glucocerebrosidase Glyco_Hydro 57% 68%  
 
 
 
 
 
 
 
 
 
 
 
Zebrafish: a new model of Parkinson’s disease                                                              | Conclusion 
 
41 
 
6. Conclusion 
 
This project, using transgenic zebrafish lines, opens new doors for the study of PD. 
The purpose of this thesis was to demonstrate the viability of Zebrafish as a model to study PD 
and to develop several transgenic lines to further study the hallmarks of PD in this organism. 
Three different tg lines have been successfully initiated. As a starting point, we have created 
two control lines: THzeb:GFP and THrat:IRES:GFP. These control lines serve different purposes. 
They will be used as controls of other developed lines with the constructs. THzeb:IRES:GFP, to 
analyze the role of IRES sequence, and THrat:a-syn:IRES:GFP to study the effect of a-syn, 
respectively. The later construct, THrat:a-syn:IRES:GFP, has already been injected in zebrafish 
embryos to further study the role of a-syn.  
Bioinformatic analysis of PD associated genes showed that the homology of human and 
Zebrafish orthologues is greater than 40%, and the functional domains are conserved between 
them in all studied proteins. Danio rerio has only one gene orthologue to the human ATP13a2- 
ATP13a5 proteins, phylogenetically closer to ATP13a2. The results from our WISH studies 
demonstrated that this gene is expressed during embryogenesis. Regarding Lrrk2, there is a 
high range of identity between the different domains between 10 to 63%, with the more 
conserved domains being responsible for the enzymatic activity of this protein. From the 
studied proteins, Synphilin-1, with its 93% similarity in the functional domain, is the more 
conserved protein during evolution. For GBA, the homology of both total sequence and 
functional domain is around 50%. 
Altogether, these results suggests that zebrafish can be a good animal model to study PD, and 
a remarkable in vivo tool to better understand the molecular mechanisms and behavior 
patterns underlying PD. 
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7. Future Work 
 
Two new constructs are being developed: THzeb:IRES:GFP and THzeb:a-syn:IRES:GFP. 
These two lines are comparable between them, and we will analyze the effect of a-syn 
under the control of a promoter specific for zebrafish. The comparison of the first 
construct with the THzeb:GFP, already generated, will enable to investigate if the IRES 
sequence influences the construct expression. If so, new alternatives for the 
generation of the constructs must be studied.  
In addition, two other constructs will be generated with the Nestin promoter. This 
promoter, contrary to tyrosine hydroxylase that is specific for dopaminergic neurons, is 
ubiquitously expressed in all the Zebrafish brain. This will provide important 
knowledge on the effect of the human a-syn expression in all the brain. These 
constructs will be developed after the analysis of the effect of the IRES sequence.  
For the F1 generation, biochemical and molecular studies will be performed. More 
specifically, the expression of a-syn will be analyzed by western-blot and by 
immunofluorescence. From this generation on, behavioral tests will be performed to 
observe both the effects of a-syn overexpression and also the effects of specific 
parkinsonism-inducible drugs like MPTP in these lines. 
Concerning the bioinformatics studies, new WISH for Lrrk2 will be performed with 
different probes. Probes for Synphilin-1 and GBA are being developed to perform WISH 
in the same stages of embryonic development. 
As a final goal, we will probe for Zebrafish a-syn using degenerate primers, and study 
its expression pattern during embryonic development to adult fish. The presence of a 
12 amino-acid constant sequence specific for a-syn between several species facilitates 
the use of this technique. 
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10.  Annexes 
 
 Annex 1 
 
Annex 1 –pMiniTol2 vector. This vector is specific for the Tol2 transposase technique. 
AmpR: Resistance for the ampicilin gene, used for selection in E.coli. M13F and M13R: 
local of recognition for M13 primers. M13 Phage is used Vectors for DNA Sequencing, 
Cloning and Expression Vectors,. 
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Annex 2 
 
 
Annex 2- pIRES-hrGFP-1a. Ampicilin: Resistance for the ampicilin gene, used for 
selection in E.coli; pCMV: strong human promoter for cytomegalovirus; SV40 pA: 
polyadenylation signal; IRES: Internal Ribossome entry site; Flag: Flag epitope; hrGFP: 
humanized recombinant GFP; pUC: origin for replication and growth in E.Coli; F1 ori: 
origin of replication for phages; MCS: Multiple Cloning Site. 
